CSPC PHARMA(01093): Amlodipine Emulsion for Injection Obtains Drug Registration Certificate

CSPC PHARMA (01093) announced that the group's development of amlodipine emulsion for injection (50ml:25mg, 100ml:50mg) has obtained a drug registration approval from the China National Medical Products Administration. This product is a dihydropyridine calcium channel blocker antagonist, belonging to the class of fast-acting intravenous antihypertensive drugs. It is suitable for treating hypertensive patients who are not suitable for oral administration or for whom oral medication is not effective. Compared to commonly used clinical medications, this product has the following significant advantages: faster onset of action, allowing for rapid, real-time, and precise blood pressure control; more suitable for patients with abnormal liver and kidney function who do not need to adjust the dosage during treatment; no need for dilution when using, which can significantly benefit individuals at risk of fluid overload. The approval of this product will further enrich the group's product pipeline in the field of cardiovascular and cerebrovascular disease treatment, enhance the group's competitiveness in this area, and potentially fill the clinical need gap for emergency treatment of hypertension.